JNJ,PFE -

. Currency in USD
-
-
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Amgen Gets EU Nod to Add Survival Data on Blincyto's Label
    Zacks41 minutes ago

    Amgen Gets EU Nod to Add Survival Data on Blincyto's Label

    Amgen (AMGN) gets approval from the European Commission to add overall survival (OS) data from the TOWER study on the label of its leukemia drug, Blincyto.

  • A Look at Allergan’s Valuation as of June 19
    Market Realist48 minutes ago

    A Look at Allergan’s Valuation as of June 19

    Allergan (AGN), a leading specialty pharmaceutical company, is focused on developing, manufacturing, and commercializing pharmaceutical and biologic products.

  • Forbes3 hours ago

    There Go Those Drug Companies Inventing New Diseases Again

    Another quote used by Walsh, this one from Cindy Pearson of the National Women’s Health Network, claims that “Osteopenia is disease-mongering plain and simple.” Osteopenia is a term used to describe bone-thinning and is considered to be the mid-point between healthy bone and osteoporosis. Is osteopenia (bone-thinning) a disease?

  • Sarepta's Stock Soars on Encouraging Gene Therapy Results
    Zacks3 hours ago

    Sarepta's Stock Soars on Encouraging Gene Therapy Results

    Sarepta (SRPT) shares skyrocket on better-than-expected results from an early-stage study, evaluating its gene therapy as a treatment for DMD patients.

  • Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks
    Motley Fool5 hours ago

    Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks

    J&J's dividend is good. But these are even better.

  • Here’s how much Houston public companies spent on litigation in 2017
    American City Business Journals5 hours ago

    Here’s how much Houston public companies spent on litigation in 2017

    Meanwhile, the nation’s largest banks are preparing for a timeout from the courtroom following years of being pummeled by shareholder and investor lawsuits in the wake of the Great Recession.

  • What’s the Latest on Teva’s Fremanezumab?
    Market Realist18 hours ago

    What’s the Latest on Teva’s Fremanezumab?

    Teva’s (TEVA) much-awaited migraine drug, Fremanezumab, is in late-stage trials for the treatment of cluster headaches. The company provided an update regarding its Enforce Phase III clinical development program for the treatment of cluster headaches on June 15.

  • TheStreet.com20 hours ago

    The Charts and Indicators on Johnson & Johnson Are Still Mostly Bearish

    is another company that Jim Cramer put in his new GLOOM index last night on his Mad Money show on CNBC. In this updated daily bar chart of JNJ, below, we have more bearish signals than bullish ones. JNJ broke down below the rising 50-day moving average line in late January and the slope of the line quickly turned negative.

  • Bloomberg21 hours ago

    Opioid Ruling Could Send  Purdue, Drugmakers to Court

    Purdue Pharma LP, Johnson & Johnson and other opioid makers faced one of the first extensive review of their legal defenses to state claims that they violated consumer-protection laws and created a public nuisance with the sale of the pain killers. New York state court Judge Jerry Garguilo on Monday rejected the pharma companies’ requests for the lawsuits be thrown out on a myriad of grounds, concluding lawyers for eight counties could move forward with their claims. While the ruling is based solely on New York law, it could provide a roadmap for other judges around the U.S. weighing whether states and local governments can proceed with claims that Purdue and other opioid makers understated the risks of prescription opioids and overstated their benefits.

  • Myriad Genetics Wins FDA SPMA Nod for BRACAnalysis CDx
    Zacksyesterday

    Myriad Genetics Wins FDA SPMA Nod for BRACAnalysis CDx

    The FDA accepts Myriad Genetics' (MYGN) supplementary premarket approval (sPMA) application for BRACAnalysis CDx to identify the best responders to Pfizer's PARP inhibitor, talazoparib.

  • Forbesyesterday

    A Gene Therapy Appears To Replace Missing Protein In Muscular Dystrophy Patients

    An experimental gene therapy appeared to dramatically increase the production of a muscle-making protein in three young boys with Duchenne muscular dystrophy, a deadly and irreversible disease, according to results being presented by the drugmaker Sarepta Therapeutics at an investor event this morning. “We think this has huge implications for the treatment of this disease,” says Jerry R. Mendell, the principal investigator in the Center for Gene Therapy at the Research Institute of Nationwide Children’s Hospital, who is leading the study for Sarepta. “Being in this field doing clinical research for many years, I learned to be cautious,” says Ron Crystal, chairman of genetic medicine at Weill Cornell Medicine.

  • Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
    PR Newswireyesterday

    Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

    NEW BRUNSWICK, N.J., June 19, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, July 17, to review second-quarter results.  Alex Gorsky, Chairman and Chief Executive Officer and Joseph J. Wolk, Executive Vice President, Chief Financial Officer will host the call. The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of the webcast will be available approximately three hours after the conference call concludes.

  • Business Wireyesterday

    Pfizer Invites Public To View And Listen To Webcast Of July 31 Conference Call With Analysts

    Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, July 31, 2018. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2018 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors.

  • Myriad Stock Rose on FDA Supplementary Premarket Approval
    Market Realistyesterday

    Myriad Stock Rose on FDA Supplementary Premarket Approval

    On June 18, Myriad Genetics (MYGN) announced that the FDA accepted its supplementary premarket approval (or sPMA) application for BRACAnalysis CDx, a companion diagnostic with Pfizer’s (PFE) talazoparib, a PARP (poly ADP ribose polymerase) inhibitor. Pfizer has already filed a new drug application (or NDA) for the approval of talazoparib. The FDA has granted Pfizer’s NDA for talazoparib “priority review” status and provided a Prescription Drug User Fee Act action date of December 2018.

  • 3 Stocks That Are Absurdly Cheap Right Now
    Motley Foolyesterday

    3 Stocks That Are Absurdly Cheap Right Now

    When stocks become nonsensically priced due to irrational market decisions, investors should act on the opportunity.

  • Reutersyesterday

    FOCUS-After split from Actelion, Idorsia CEO plans to raise more cash in 2019

    Swiss biotech Idorsia, spun off from Actelion last June with a $1 billion investment from buyer Johnson & Johnson, will seek fresh funding in 2019 to support late-stage trials of drugs getting underway, its CEO told Reuters. French founders Jean-Paul Clozel and his wife, Martine Clozel, sold Actelion for $30 billion last year, but only after extracting rights to 11 prized drugs in development, including an insomnia medicine nicknamed DORA.

  • Financial Timesyesterday

    [$$] Britain’s flawed medicines regime urgently needs reform

    The UK pharmaceuticals industry and the patients who rely on it are under serious threat from Brexit as well as from the flawed way medicines are developed, tested and made available to patients in the country. Leaders of our industry, which employs more than 140,000 people in the UK and contributes £30bn to gross domestic product, are meeting members of the government, including business secretary Greg Clark and international trade secretary Liam Fox, on Tuesday to discuss the country’s future as a world-leading life sciences hub. A report I compiled with PwC found that it remains a significant barrier to UK investment for many global companies.

  • Markets Right Now: Stocks look to recover from early skid
    Associated Press2 days ago

    Markets Right Now: Stocks look to recover from early skid

    NEW YORK (AP) — The latest on developments in financial markets (all times local):

  • TheStreet.com2 days ago

    3 Great Stocks for Retirees to Own

    Congratulations! You've just retired. Investors and financial planners both suggest that dividend stocks can be a great source of income for those looking to supplement their retirement savings. The blue-chip stock's staying power and brand recognition should be viewed favorably by retiree investors, says Robert Johnson, principal at the Fed Policy Investment Research Group.

  • Reuters2 days ago

    After split from Actelion, Idorsia CEO plans to raise more cash in 2019

    Swiss biotech Idorsia, spun off from Actelion last June with a $1 billion investment from buyer Johnson & Johnson, will seek fresh funding in 2019 to support late-stage trials of drugs getting underway, its CEO told Reuters. French founders Jean-Paul Clozel and his wife, Martine Clozel, sold Actelion for $30 billion last year, but only after extracting rights to 11 prized drugs in development, including an insomnia medicine nicknamed DORA. With 650 employees, Jean-Paul Clozel expects to burn through Idorsia's cash in about two years, before his drug hopefuls generate revenue - typical of the biotech industry where the risk of pipeline failures is ever-present but the rewards of striking paydirt, as was the case with Actelion, can be vast.

  • Why Geron Corporation Stock Is Heading Higher Today
    Motley Fool2 days ago

    Why Geron Corporation Stock Is Heading Higher Today

    The company's EHA conference over the weekend has investors snapping up shares today.

  • PR Newswire2 days ago

    FDA Approves the Next Generation of Customized LASIK Treatment with iDESIGN Refractive Studio

    Next generation LASIK platform that measures the eye inside and out to enable highly precise personalized vision correction Only available LASIK platform indicated for monovision LASIK in presbyopic myopic ...

  • UNF, Mayo experiment with rare 3-D microscope
    American City Business Journals2 days ago

    UNF, Mayo experiment with rare 3-D microscope

    The University of North Florida is temporarily housing a highly advanced microscope, the only one of its kind in North America.

  • Cramer floats idea for 'gloomy' ETF with Wall Street's mo...
    CNBC Videos2 days ago

    Cramer floats idea for 'gloomy' ETF with Wall Street's mo...

    Jim Cramer proposes starting a new exchange-traded fund with the stocks that scare investors most when trade tensions run high.

  • Cramer floats idea for 'gloomy' ETF
    CNBC Videos2 days ago

    Cramer floats idea for 'gloomy' ETF

    Jim Cramer proposes starting a new exchange-traded fund with the stocks that scare investors most when trade tensions run high.